Lamotrigine: Treatment of Epilepsy in the Elderly

Consultant Pharmacist

Volumn 18, Issue 11, 2003, Pages 979-992

  Lott, Rex S ^a  

^a IDAHO STATE UNIVERSITY   (United States)

Author keywords

Elderly; Epilepsy; Hypersensitivity; Lamotrigine

Indexed keywords

CARBAMAZEPINE; ENZYME ACTIVATOR; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFAMPICIN; SERTRALINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ABDOMINAL PAIN; AGED; ANTICONVULSANT THERAPY; ASTHENIA; ATAXIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; EPILEPSY; FEMUR FRACTURE; GERIATRIC CARE; GRAND MAL SEIZURE; HEADACHE; HEART INFARCTION; HEMATEMESIS; HUMAN; JAUNDICE; METABOLIC DISORDER; MONOTHERAPY; NAUSEA; NONHUMAN; PARANOIA; RASH; REVIEW; RHINITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; STOMACH ULCER; VISUAL IMPAIRMENT; VOMITING;

EID: 0842278863     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Faught E. Epidemiology and drug treatment of epilepsy in elderly people. Drugs Aging 1999;15:255-69.
2. Cloyd JC, Lackner TE, Leppik IE. Antiepileptics in the elderly: pharmacoepidemiology and pharmacokinetics. Arch Fam Med 1994;3:589-98.
3. Scheuer ML, Cohen J. Seizures and epilepsy in the elderly. Neurol Clin 1993;11:787-804.
4. Sirven JJ. Epilepsy in older adults: causes, consequences, and treatment. J Am Geriatr Soc 1998;46:1291-301.
5. Rowan AJ. Reflections on the treatment of seizures in the elderly population. Neurology 1998;51(suppl 4):S28-S33.
6. Ramsay RE, Pryor F. Epilepsy in the elderly. Neurology 2000;55(suppl 1):S9-S14.
7. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
8. Cameron H, Macphee GJA. Anticonvulsant therapy in the elderly - a need for placebo-controlled trials. Epilepsy Res 1995;21:149-57.
9. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32:554-63.
10. Lott RS, McAuley J. Seizure disorders. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. 7th ed. New York, NY: Lippincott Williams & Wilkins; 2001.
11. Marson AG, Kadir ZA, Hutton JL et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38:859-80.
12. Datta PK, Crawford PM. Refractory epilepsy: treatment with new antiepileptic drugs. Seizure 2000;9:51-7
13. Leach MJ, Lees G, Riddall DR. Lamotrigine: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York, NY: Raven Press; 1995.
14. Stefani A, Spadoni F, Bernardi G. Voltage-activated calcium channels: targets of antiepileptic drug therapy? Epilepsia 1997;38:959-65.
15. Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 2002;5:767-74.
16. Zona C, Tancredi V, Longone P et al. Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine. Epilepsia 2002;43:685-90.
17. Burstein AH. Lamotrigine. Pharmacotherapy 1995;15:129-43.
18. Gilman JT. Lamotrigine: an antiepileptic agent for the treatment of partial seizures. Ann Pharmacother 1993;51:1018-25.
19. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993;25:433-43.
20. Cohen AF, Land GS, Breimer DD et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-41.
21. Lamictal prescribing information. GlaxoSmithKline, Research Triangle Park, NC. January 2003.
22. Yuen WC, Peck AW. Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Br J Clin Pharmacol 1988;26:242P (Abstract).
23. Nihata MC, Morosco RS, Hipple TF. Stability of lamotrigine in two extemporaneously prepared oral suspensions at 4 and 25 degrees C. Am J Health Syst Pharm 1999;56:240-2.
24. Birnbaum AK, Kriel RL, Im Y et al. Relative bioavailability of lamotrigine chewable dispersible tablets administered rectally. Pharmacotherapy. 2001;21:158-62.
25. Birnbaum AK, Kriel RL, Burkhardt RT et al. Rectal absorption of lamotrigine compressed tablets. Epilepsia 2000;41:850-3.
26. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991;1:121-8.
27. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997;43:457-65.
28. Grasela TH, Fiedler-Kelly J, Cox E et al. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 1999;39:373-84.
29. Wooton R, Soul-Lawton J, Rolan PE et al. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol 1997;43:23-7.
30. Marcellin P, de Bony F, Garret C et al. Influence of cirrhosis on lamotrigine pharmacokinetics. Br J Clin Pharmacol 2001;51:410-4.
31. Kilpatrick ES, Forrest G, Brodie MJ. Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia 1996;37:534-8.
32. Kanner AM, Chkenkely I, Frey M. Is there a relationship between the occurrence of adverse events from lamotrigine and its serum concentrations? [abstract] Epilepsia 1998;39(suppl 6):S72-S73.
33. Gidal BE, Welty TE. The concentration-effect relationship with lamotrigine (LTG). Epilepsia 1997;38:260.
34. Morris RG, Black AB, Harris AL et al. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 1998;46:547-51.
35. Fröscher W, Keller F, Vogt H et al. Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels. Epileptic Disord 2002;1:49-55.
36. Matsuo F, Bergen, D, Faught E et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91.
37. Messenheimer J, Ramsay RE, Wilmore LJ et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35:113-21.
38. Ramaratnam S, Marson AG, Baker GA. Lamotrigine add-on for drug-resistant partial epilepsy (Cochrane Review). In: The Cochrane Library, Issue 2. 2001. Oxford, England: Update Software 2001.
39. Pellock JM. Treatment of epilepsy in the new millennium. Pharmacotherapy 2000;20(8 pt 2):129S-138S.
40. Mott J, Trevathan E, Arvidsson JF et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997;337:1807-12.
41. Gilliam F, Vazquez B, Sackellares JC et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018-25.
42. Steiner TJ, Dellaportas CI, Findley LJ et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40:601-7.
43. Jozwiak S, Terczynski A. Open study evaluating lamotrigine efficacy and safety in addon treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy. Seizure 2000;9:486-92.
44. Nieto-Barrera M, Brozmanova M, Capovilla G et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res 2001;46:145-55.
45. Brodie MJ, Chadwick DW, Anhut H et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002;43:993-1000.
46. Biton V, Natara S, Ramsay RE et al. Dosing algorithm for conversion from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy [abstract]. Neurology 2003;60(suppl 1):A476.
47. Reunanen M, Dam M, Yuen AWC. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23:149-55.
48. Brodie MJ, Overstall PW, Giorgi L et al. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999;37:81-7.
49. Hurley SC. Lamotrigine update and its use in mood disorders. Ann Pharmacother 2002;36:860-73.
50. Ebert U, Thong NQ, Oertel R et al. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol 2000;56:299-304.
51. Giorgi L, Gomez G, O'Neill F et al. The tolerability of lamotrigine in elderly patients with epilepsy. Drugs Aging 2001;18:621-30.
52. Anderson GD, Gidal BE, Messenheimer JA et al. Time course of lamotrigine deinduction: impact of step-wise withdrawal of carbamazepine of phenytoin. Epilepsy Res 2002;49:211-7.
53. Richens A. Lamotrigine: Toxicity. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York, NY: Raven Press; 1995.
54. Gidal BE, Nanry KP, Sheth RD et al. Lamotrigine pharmacokinetics in the presence of low dose VPA and during conversion to monotherapy. Epilepsia 2001;42(suppl 7):89. Abstract 1.281.
55. Sale M, Gidal B, Blum D. Optimizing lamotrigine blood levels during conversion from valproate/lamotrigine combination to lamotrigine monotherapy. Epilepsia 2002;43 (suppl 7):107. Abstract 1. 293.
56. Anderson GD, Yau MK, Gidal BE et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996;60:145-56.
57. Besag FMC, Berry DJ, Pool F et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998;39:183-7.
58. Eriksson A-S, Boreus LO. No increase in carbamazepine-10,11-epoxide during addition of lamotrigine treatment in children. Ther Drug Monit 1997;19:499-501.
59. Gidal BE, Rutecki P, Shaw R et al. Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. Epilepsy Res 1997;28:207-11.
60. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998;7:163-5.
61. Pellock JM. The clinical efficacy of lamotrigine as an antiepileptic drug. Neurology 1994;44(suppl 8):S29-S35.
62. Mackay FJ, Wilton LV, Pearce GL et al. Safety of long-term lamatrigine in epilepsy. Epilepsia 1997;38:881-6.
63. Wong ICK, Mawer GE, Sander JWAS. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. Epilepsia 2001;42:237-44.
64. Betts T, Goodwin G, Withers RM et al. Human safety of lamotrigine. Epilepsia 1991;32(suppl 2):S17-S21.
65. Sinclair K, Martin RC, Faught ER et al. Tolerability of lamatrigine and carbamazepine in healthy senior adults [abstract]. Epilepsia 2000;41 (suppl 7):255.
66. Rzany B, Correia O, Kelly JP et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Lancet 1999;353:2190-4.
67. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002;8:5.
68. Guberman AH, Besag FMC, Brodie MJ et al. Lamotrigine-associated skin rash: risk/benefit considerations in adults and children. Epilepsia 1999;40:985-91.
69. Schlienger RG, Knowles SR, Shear NH. Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998;51:1172-5.
70. Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998;25:S14-S18.
71. Brodie MJ, Yuen AWC. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res 1997;26:423-32.
72. Tavernor SJ, Wong ICK, Newton R et al. Rechallenge with lamotrigine after initial rash. Seizure 1995;4:67-71.
73. Meador KJ. Current discoveries on the cognitive effects of antiepileptic drugs. Pharmacotherapy 2000;20(8, pt 2):185S-190S.
74. Martin R, Meador K, Turrentine L et al. Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia 2001;42:764-71.
75. Meador KJ, Loring DW, Ray PG et al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology 2001;56:1177-82.
76. Aldenkamp AP, Arends J, Bootsma HPR et al. Randomized double-blind parallel-group study comparing cognitive effects of low-dose lamotrigine and valproate and placebo in healthy volunteers. Epilepsia 2002;43:19-26.
77. Biton V, Mizra W, Montouris G et al. Weight change associated with valproate and famotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7.
78. Devinsky O, Vuong A, Hammer A et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000;54:973-5.
79. Matsuo F, Gay P, Madsen J et al. Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study. Epilepsia 1996;37:857-62.